Investigating new treatments for cancer by targeting gene regulation mechanisms.

Allosteric Modulators of Polycomb Repressive 2 Gene Repression as Potential Therapeutics for the Development of Novel Epigenetic Cancer Therapies

NIH-funded research Brooklyn College · NIH-10810634

This study is exploring new cancer treatments that target a specific protein complex called PRC2, which is involved in how genes are controlled, with the hope of creating better therapies for patients to improve their chances of recovery and lower the risk of cancer coming back.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionBrooklyn College NIH-funded
Lab location1 site (New York, United States)
Project IDNIH-10810634 on NIH RePORTER

What this research studies

This research focuses on developing new anticancer therapies that target the polycomb repressive complex 2 (PRC2), which plays a crucial role in gene regulation through epigenetic modifications. By understanding how PRC2 contributes to cancer development, the researchers aim to create allosteric modulators that can effectively inhibit its function. The approach involves studying the mechanisms of PRC2 and its components, particularly in relation to their overexpression in various cancers. Patients may benefit from potential new treatments that could improve outcomes and reduce the risk of cancer recurrence.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with cancers associated with PRC2 overactivity.

Not a fit: Patients with cancers not linked to PRC2 dysregulation may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to innovative cancer therapies that improve survival rates and quality of life for patients.

How similar studies have performed: Previous research has shown promise in targeting PRC2, but this approach aims to develop novel inhibitors that have not yet been tested.

Where this research is happening

New York, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer AgentsCancer DrugNeoplastic Disease Chemotherapeutic Agentsanti-cancer drug
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.